Why the study?
Does USP18 protect against hepatic steatosis and insulin resistance?
Does USP18 protect against hepatic steatosis and insulin resistance?
USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity on TAK1.
Answers are grounded in this paper and cite their sources.
May identify USP18-TAK1 as therapeutic target in steatosis; hypothesis-generating in animals and leaves open human translation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
An et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: